Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of JNJ-80038114, a T-Cell Redirecting Agent Targeting Prostate Specific Membrane Antigen (PSMA), for Advanced Stage Prostate Cancer
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-80038114 in Part 1 (dose escalation) and to determine the safety at the RP2D(s) in Part 2 (dose expansion).
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
University Of Minnesota
Minneapolis, Minnesota, United States
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
University College London Hospitals NHSFT
London, United Kingdom
The Christie NHS Foundation Trust Christie Hospital
Manchester, United Kingdom
Royal Marsden Hospital
Sutton, United Kingdom
Start Date
November 15, 2022
Primary Completion Date
March 26, 2024
Completion Date
March 31, 2024
Last Updated
March 4, 2025
39
ACTUAL participants
JNJ-80038114
DRUG
Lead Sponsor
Janssen Research & Development, LLC
NCT07225946
NCT04868604
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00756665